about
Follicular lymphoma: 2012 update on diagnosis and managementGood things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomasPrognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysisAnthracycline-containing regimens for treatment of follicular lymphoma in adultsAnthracyclines-containing regimens for treatment of follicular lymphoma in adultsInterferon-alpha for maintenance of follicular lymphomaRituximab as maintenance therapy for patients with follicular lymphomaChemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphomaUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphomaIdelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potentialDiagnosis of follicular lymphoma of the gastrointestinal tract: A better initial diagnostic workupFollicular lymphoma: 2011 update on diagnosis and managementConsolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspectiveRole of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphomaFollicular lymphoma: 2014 update on diagnosis and managementPrognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic reviewTargeting CD19 in B-cell lymphoma: emerging role of SAR3419Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older PatientsThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraDanish National Lymphoma RegistryNext-generation surveillance strategies for patients with lymphomaRadiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 YearsLong-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.When to treat patients with relapsed follicular lymphoma.Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphomaInherited genetic variation and overall survival following follicular lymphoma.A systematic approach to the diagnosis of suspected central nervous system lymphoma.Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaDetermination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.The Danish National Lymphoma Registry: Coverage and Data QualityValidation of the JCOG prognostic index in advanced gastric cancer using individual patient data from the SPIRITS and G-SOX trials.Primary pancreatic lymphoma--pancreatic tumours that are potentially curable without resection, a retrospective review of four casesCladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
P2860
Q22252956-DB7CC64E-91CB-4350-A543-5499D2FDBC7FQ22305693-483D1051-DD3A-4ACB-85D3-1007E5297636Q24186840-38659600-7F35-469C-BB23-7A33F13A86DAQ24201306-42820DE9-DCD1-4DF6-BEF5-76D0630D6F47Q24236087-348D899A-FD8A-4A6C-BB78-96A3440253CFQ24240781-7C8820FC-2819-4331-8B80-E62EB23DE1B1Q24241273-0BDD96C9-CB0B-4CAB-BC4E-8BEF270FC8B9Q24243100-66EE85D1-73EE-485F-BFF4-06EC63E1BB48Q24633710-6583B468-D0BF-46B3-89D0-26B00A083A8BQ26747753-AEF914F1-7C5D-4470-9A35-0F125A7BA890Q26773194-979DC6E3-ABE3-46D6-A256-427E8AFA1E52Q26851450-EE286FF6-B512-4F5F-959A-2F0CFDB49997Q26998446-9FE386AA-CF9C-4F6D-BA51-5DFA565DD946Q27000310-3F663EFC-8C56-4A68-9E36-C7641C6422C2Q27021850-61D94C4E-3AEF-4A1A-A050-15CD1981D8B6Q27027445-170EA2EF-70D1-49CF-917F-DFD986B126F8Q27027562-68F476D2-6528-4641-BA42-9C230DFB1FD4Q28066710-0C7CB8E2-6B09-427C-B987-01855D361B59Q28072397-E643D1A9-0505-4350-9223-C073BAA4E22BQ28077997-CDF6070E-0BCB-4283-A48B-4565652E4A97Q28084956-F641BD45-EDB8-4614-97E3-84B559396E60Q28264598-3B7D0C70-E6E4-474C-B782-ED4ED5CFF4F0Q28297940-1C15A14A-C9C5-4FB1-B58F-300BF133869DQ30238528-200CA3D8-E6A0-468A-8477-46916A95EEA4Q30419228-96223669-FB64-4BD7-85E6-6E3B61C39A57Q30519549-347708E7-F4F5-4F9D-BAC8-106F658D223AQ30586022-81EA991F-FCC1-40A3-A0D4-17F76792B719Q30649483-F1BD64B8-C22C-415F-BC44-4A78B1796A58Q30785622-9CD9BD20-0A49-40BA-845F-CF6093738FF9Q31110238-48A917DE-5F48-4894-9C15-C1491F6AF420Q31162395-EA5EA963-0EC3-466F-A85A-E8DAF153228BQ33242286-046F987B-28F1-4086-82D9-0683A2E84570Q33392784-BFCA663A-FDF8-4006-89F1-1BE951777D0FQ33403958-C5D1E7FC-2BDB-4EDC-928A-AFA175B93774Q33405150-FCD65834-B818-4173-B2AB-3EC9A37682F5Q33412158-845207FF-0E6E-42B7-85C6-6C9D78CF1F0BQ33416554-68A40E6F-1DA5-46A4-8CEA-7474AA850A8EQ33418964-94B6E2B5-0C1B-4359-B873-AC1946491630Q33424956-AE389063-7C99-4E7C-A91B-EFC6259CF78BQ33574197-138049E2-BA8E-4097-BD54-8021A8E64368
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Follicular lymphoma international prognostic index.
@en
Follicular lymphoma international prognostic index.
@nl
type
label
Follicular lymphoma international prognostic index.
@en
Follicular lymphoma international prognostic index.
@nl
prefLabel
Follicular lymphoma international prognostic index.
@en
Follicular lymphoma international prognostic index.
@nl
P2093
P50
P1433
P1476
Follicular lymphoma international prognostic index.
@en
P2093
Ama Rohatiner
Andrew T Lister
Anton Hagenbeek
Armando Lopez-Guillermo
Bertrand Coiffier
Cesare Guglielmi
Chantal Doyen
Corinne Haïoun
Dolores Caballero
Emili Montserrat
P304
P356
10.1182/BLOOD-2003-12-4434
P407
P577
2004-05-04T00:00:00Z